Cerus Corporation (NASDAQ:CERS) announced today that Dr. Laurence
Corash, chief medical officer, is scheduled to present a corporate
update at the Stephens Fall Investment Conference in New York at 1:00 PM
ET on Wednesday, November 14, 2012.
A live webcast of the presentation will be available from the Investor
Relations page of the Cerus web site at http://www.cerus.com/ir.
A replay will be available for approximately two weeks following the
completion of the event.
Cerus Corporation is a biomedical products company focused on
commercializing the INTERCEPT Blood System to enhance blood safety. The
INTERCEPT system is designed to reduce the risk of
transfusion-transmitted diseases by inactivating a broad range of
pathogens such as viruses, bacteria and parasites that may be present in
donated blood. The nucleic acid targeting mechanism of action enables
INTERCEPT treatment to inactivate established transfusion threats, such
as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed
to inactivate emerging pathogens such as influenza, malaria and dengue.
Cerus currently markets and sells the INTERCEPT Blood System for both
platelets and plasma in Europe, the Commonwealth of Independent States,
the Middle East and selected countries in other regions around the
world. The INTERCEPT red blood cell system is in clinical development.
for more information.
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus